Advertisement

Progressive Systemic Scleroderma

  • Nicolas Hunzelmann
  • Thomas Krieg

Keywords

Systemic Sclerosis Connective Tissue Growth Factor Progressive Systemic Sclerosis Porphyria Cutanea Tarda Localize Scleroderma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Artlett CM, Smith CB, Jimenez SA (1998) Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 338: 1186–1191CrossRefPubMedGoogle Scholar
  2. Badesch D, Tapson VF, McGoon MD (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Int Med 132: 425–434PubMedGoogle Scholar
  3. Black CM, Silman SJ, Herrick AI (1998) Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double blind, placebo-controlled trial. Arthritis Rheum 42: 299–305CrossRefGoogle Scholar
  4. Blockmans D, Beyens G, Verhaege R (1996) Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases. Clin Rheumatol 15: 148–153PubMedGoogle Scholar
  5. Bottomley WW, Goodfield MJ, Sheehan-Dare RA (1996) Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. Br J Dermatol 135: 302–302PubMedGoogle Scholar
  6. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM (1998) Anti-RNA Polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 37: 15–20CrossRefPubMedGoogle Scholar
  7. Burastero SE, Galbiati S, Vassallo A, Sabbadini MG, Bellone M, Marchionni L et al. (2003) Cellular microchimerism as a lifelong physiologic status in parous women: an immunologic basis for its amplification in patients with systemic sclerosis. Arthiritis Rheum 48: 1109–1116CrossRefGoogle Scholar
  8. Chang YJ, Spiera H (1999) Renal transplantation in scleroderma. Medicine 78: 382–385PubMedGoogle Scholar
  9. Clements PJ, Lachenbruch PA, Ng SC (1990) Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 33: 1256–1263PubMedGoogle Scholar
  10. Clements PJ, Furst DE (1997) Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation. J Rheumatol 24: 85–88Google Scholar
  11. Clements PJ, Furst DE, Wong WK (1999) High dose versus low dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two year, double blind, randomized, controlled clinical trial. Arthritis Rheum 42: 1194–203CrossRefPubMedGoogle Scholar
  12. Denton CP, Sweny P Abdulla A, Black CM (1994) Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 33: 90–92PubMedGoogle Scholar
  13. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ et al. (2002) Deficient Smad 7 expression: aputative molecular defect in scleroderma. PNAS 99: 3908–13CrossRefPubMedGoogle Scholar
  14. Duncan MR, Hasan A, Berman B (1995) Pentoxifylline, pentifylline and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 downregulation. J Invest Dermatol 104: 282–286CrossRefPubMedGoogle Scholar
  15. Dziadzio M, Denton CP Smith R (1999) Losartan therapy for raynauds phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel group, controlled trial. Arthritis Rheum 42: 2646–2455CrossRefPubMedGoogle Scholar
  16. Eckes B, Mauch C, Huppe G, Krieg T (1996) Differential regulation of transcription and transcript stability of pro a1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic sclerosis. Biochem J 315: 549–553PubMedGoogle Scholar
  17. Enomoto, Mekkes JR, Bossuyt PM (1999) Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 41: 915–922PubMedGoogle Scholar
  18. Evans PC, Lambert N, Maloney S (1999) Long term fetal microchimerism in peripheral blood mononuclear scell subsets in healthy women and women with scleroderma. Blood 93: 2033–2037PubMedGoogle Scholar
  19. Fritzler MJ (1993) Autoantibodies in scleroderma. J Dermatol 20: 257–268PubMedGoogle Scholar
  20. Furst DE, Clements PJ, Steen VD (1998) The modified rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25: 84–88PubMedGoogle Scholar
  21. Genth E, Mierau R, Genetzky P (1990) Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum 33: 657–665PubMedGoogle Scholar
  22. Jablonska S, Blaszyk M (1999) Scleroderma Overlap Syndromes. Adv Exp Med Biol 455: 85–92PubMedGoogle Scholar
  23. Janowsky EC, Kupper LL, Hulka BS (2000) Meta-analyses of the relation between silicone breast implants and the risk of connective tissue. N Engl J Med 342: 781–790CrossRefPubMedGoogle Scholar
  24. Haustein UF, Anderegg U (1998) Silica induced scleroderma — clinical and experimental aspects. J Rheumatol 25: 1917–1926PubMedGoogle Scholar
  25. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43: 889–93CrossRefPubMedGoogle Scholar
  26. Heickendorff L, Zachariae H, Bjerring P, Halkier-Sorensen L, Sondergaard K (1995) The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. J Am Acad Dermatol 32: 584–588CrossRefPubMedGoogle Scholar
  27. Herrmann K, Heckmann M, Kulozik M, Haustein UF, Krieg T (1991) Steady state mRNA levels of collagens I,III, fibronectin and collagenase in skin biopsies of systemic sclerosis patients. J Invest Dermatol 97: 219–225CrossRefPubMedGoogle Scholar
  28. Herrmann G, Wlaschek M, Lange TS, Prenzel K, Goerz G, Scharffetter-Kochanek K (1993) UVA irradiation stimulates the synthesis of various matrix-metalloproteinases (MMPs) in cultured human fibroblasts. Exp Dermatol 2: 92–97PubMedGoogle Scholar
  29. Hoeper MM et al. (2000) Long term treatment of primary pulmonary hypertension with aerolized iloprost, a prostacyclin analogue. N Engl J Med 342: 1866–70CrossRefPubMedGoogle Scholar
  30. Hunzelmann N, Anders S, Fierlbeck G, Hein R, Herrmann K, Albrecht M, Bell S, Thur J, Muche R, Adelmann-Grill B, Wehner-Caroli J, Gaus W, Krieg T (1997) Systemic scleroderma: multicenter trial of one year treatment with recombinant interferon-gamma. Arch Dermatol 133: 609–613CrossRefPubMedGoogle Scholar
  31. Hunzelmann N, Risteli J, Risteli L, Sacher C, Black CM, Krieg T (1998a) Increased circulating concentrations of the type I collagen specific degradation product ICTP in systemic sclerosis reflect the extent of skin involvement: A new serum marker for clinical severity in SSc patients. Br J Dermatol 139: 1020–1025CrossRefPubMedGoogle Scholar
  32. Hunzelmann N, Scharfetter-Kochanek K, Hager C, Krieg T (1998b) Management of localized scleroderma. Sem Cutan Med Surg 17: 34–41Google Scholar
  33. Igarashi A, Nashiro K, Kikuchi K (1995) Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 105: 280–284CrossRefPubMedGoogle Scholar
  34. Jimenez SA and Saitta B (2000) Alterations in the regulation of expression of the a1(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma). Springer Semin Immunopathol 21: 397–414Google Scholar
  35. Kahaleh MB, Sultany GL, Smith EA, Huffstetter JE, Loadholt CB, LeRoy EC (1986) A modified scleroderma skin scoring method. Clin Exp Rheumatol 4: 367–369PubMedGoogle Scholar
  36. Kahaleh M, Fan PS (1997) Mechanism of serum mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 83: 32–40CrossRefPubMedGoogle Scholar
  37. Kerscher M, Meurer M, Sander C, Volkenandt M, Lehmann P, Plewig G, Röcken M (1996) PUVA bath photochemotherapy for localized scleroderma. Arch Dermatol 132: 1280–1282CrossRefPubMedGoogle Scholar
  38. Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T (1990) Co-localization of transforming growth factor ß2 with al(1) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 86: 917–921PubMedGoogle Scholar
  39. LeRoy EC (1974) Increased collagen synthesis by scleroderma fibroblasts in vitro. J Clin Invest 54: 880–889PubMedGoogle Scholar
  40. Lunardi C (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nature Med 6: 1183–1186CrossRefPubMedGoogle Scholar
  41. Majewski S, Hunzelmann N, Johnson JP, Jung C, Mauch C, Ziegler-Heitbrock H, Riethmüller G, Krieg T (1991) Expression of intercellular adhesion molecule-1 (ICAM-1) on fibroblasts in the skin of patients with systemic sclerosis. J Invest Dermatol 97: 667–671CrossRefPubMedGoogle Scholar
  42. Marguerie C (1992) The clinical and immunogenetic features of patients with autoantibodies to the nucleolar anitgen PM-Scl. Medicine 71: 327–336PubMedGoogle Scholar
  43. Maricq H, LeRoy E, Dangelo W (1980) Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23: 183–189PubMedGoogle Scholar
  44. Mauch C (1998) Regulation of connective tissue turnover by cell-matrix interactions. Arch Dermatol Res 290: S30–36PubMedGoogle Scholar
  45. McCormick LL, Zhang Y, Tootell E, Gilliam AC (1999) Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 163: 5693–5699PubMedGoogle Scholar
  46. McKown KM, Carbone LD, Bustillo J (2000) Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 43: 1054–1061CrossRefPubMedGoogle Scholar
  47. Perlish JS, Lemlich G, Fleischmajer R (1988) Identification of collagen fibrils in scleroderma skin. J Invest Dermatol 90: 48–54CrossRefPubMedGoogle Scholar
  48. Pigula FA, Griffith BP, Zenati MA (1997) Lung transplantation for respiratory failure resulting from systemic disease. Ann Thorac Surg 64: 1630–1634CrossRefPubMedGoogle Scholar
  49. Poormoghim H, Lucas M, Fertig N, Medsger TA (2000) Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty eight patients. Arthritis Rheum 43: 444–451CrossRefPubMedGoogle Scholar
  50. Pope J, Bellamy N, Seibold J (1998) A controlled trial of methotrexate versus placebo in early diffuse scleroderma — preliminary analysis. Arthritis Rheum 41: S420Google Scholar
  51. Pope J, Fenlon D, Thompson A (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2: CD000953PubMedGoogle Scholar
  52. Prescott RJ, Freemont A, Jones C (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166: 255–263PubMedGoogle Scholar
  53. Rook AH, Freundlich B, Jegasothy BV (1992) Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol 128: 337–346CrossRefPubMedGoogle Scholar
  54. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM et al. (2002) Bosentan therapy for pulmonary hypertension. NEJM 346: 896–903CrossRefPubMedGoogle Scholar
  55. Scharffetter K, Lankat-Buttgereit B, Krieg T (1988) Localization of collagen mRNA in normal and scleroderma skin by in situ hybridization. Eur J Clin Invest 18: 9–17PubMedGoogle Scholar
  56. Scharffetter K, Wlaschek M, Hogg A, Bolsen K, Schothorst A, Goerz G, Krieg T, Plewig G (1991) UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 283: 506–511CrossRefPubMedGoogle Scholar
  57. Seibold J (1994) Systemic sclerosis. In: Klipped J, Dieppe P, Mosby St. Louis (Eds) Rheumatology, 8.1–8.14Google Scholar
  58. Seibold J, Korn J, Simms R (2000) Recombinant human relaxin in the treatment of scleroderma. A randomized, double blind, placebo-controlled study. Ann Int Med 132: 871–879PubMedGoogle Scholar
  59. Sgonc R, Gruschwitz M, Dietrich H (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98: 785–792PubMedGoogle Scholar
  60. Shi-Wen X, Pennington D, Holmes A (2000) Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 25: 213–224CrossRefGoogle Scholar
  61. Sjogren RW (1996) Gastrointestinal features of scleroderma. Curr Opin Rheumatol 8: 569–575PubMedGoogle Scholar
  62. Steen VD, Constantino JP, Shapiro AP, Medsger TA (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Int Med 113: 352–357PubMedGoogle Scholar
  63. Steen VD, Follansbee WP, Conte CG, Medsger TA (1996) Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum 39: 677–681PubMedGoogle Scholar
  64. Steen VD, Medsger TA (1998) Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41: 1613–1619CrossRefPubMedGoogle Scholar
  65. Stege H, Berneburg M, Humke S (1997) High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 36: 938–944PubMedGoogle Scholar
  66. Stone PJ, Korn JH, North H, Lally EV, Miller LC, Tucker LB, Strongwater S, Snider GL, Franzblau C (1995): Cross-linked elastin and collagen degradation products in the urine of patients with scleroderma. Arthritis Rheum 38: 517–524PubMedGoogle Scholar
  67. Straniero NR, Furst DE (1989) Environmentally induced systemic sclerosis like illness. Baillieres Clin Rheumatol 3: 63–79PubMedGoogle Scholar
  68. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnosis and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581–590Google Scholar
  69. Tyndall A, Black C, Finke J, Peter H, Gratwohl A (1997) Treatment of systemic sclerosis with autologous hemopoetic stem cell transplantation. The Lancet 349: 254–356CrossRefGoogle Scholar
  70. Uitto J, Bauer EA, Eisen AZ (1979) Scleroderma. Increased biosynthesis of triple helical type I and type III procollagen associated with unaltered expression of collagenase by skin fibroblasts in culture. J Clin Invest 64: 921–930PubMedGoogle Scholar
  71. van den Hoogen FH, Boerbooms AM, Swaak AJ (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double blind trial, followed by a 24 week observation trial. Br J Rheumatol 35: 364–372PubMedGoogle Scholar
  72. White B, Bauer EA, Goldsmith LA (1995) Guidelines for clinical trials in systemic sclerosis (scleroderma). I. disease modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic sclerosis. Arthritis Rheum 38: 351–360PubMedGoogle Scholar
  73. White B, Moore WC, Wigley FM (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Int Med 132: 947–954PubMedGoogle Scholar
  74. Williams HJ, Alarcon GS, Joks R (1999) Early undifferentiated connective tissue disease. VI an inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 26: 816–825PubMedGoogle Scholar
  75. Zachariae H, Halkier-Sorensen L, Bjerring P, Heickendorff L (1996) Treatment of ischemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis. Acta Derm Venereol 76: 236–238PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2005

Authors and Affiliations

  • Nicolas Hunzelmann
  • Thomas Krieg

There are no affiliations available

Personalised recommendations